Shots Fired in the Next Tax Fleeing Battle

Perpetual takeover target Shire  is officially in play.

Long rumored as a takeover candidate given its strong ADHD franchise, its orphan drug focus, and most importantly its low Irish tax rates, Shire has an actual suitor in big pharma AbbVie . However, its private solicitations weren't enough to get a deal done, so the big pharma is making its case publicly for the newest tax-fleeing, inversion deal.

Shots have been fired and Shire is fighting back. Not wanting to be an easy acquisition or even the subject of a bidding war company management made its case as a stand alone entity highlighting sustainable double digit growth that is undervalued by AbbVie's $46.5 billion offer.

In this episode of Market Check-Up, the Motley Fool's health care focused investing show, analysts David Williamson and Michael Douglass, discuss the AbbVie's offer, what makes Shire so attractive, and why a bidding war could likely emerge. Watch and find out.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


The article Shots Fired in the Next Tax Fleeing Battle originally appeared on

David Williamson owns shares of AbbVie. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story